Related Experiment Video
Updated: Sep 17, 2025
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
[Clinical characteristics and survival analysis of pediatric Hodgkin lymphoma: a multicenter study]
Ying Lin1, Li-Li Pan1, Shao-Hua LE1
1Union Clinical Medicine College of Fujian Medical University, Fuzhou 350001, China.
Insights
Pediatric Hodgkin lymphoma (HL) has a good prognosis. Large tumors at diagnosis and lack of complete response after chemotherapy indicate a poor outlook for children with this cancer.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Research
Background:
- Hodgkin lymphoma (HL) is a cancer of the lymphatic system.
- Understanding its characteristics and prognosis in children is crucial for effective treatment.
Purpose of the Study:
- To investigate the clinicopathological features of pediatric Hodgkin lymphoma.
- To identify prognostic factors influencing outcomes in children with HL.
Main Methods:
- Retrospective analysis of clinical data from children diagnosed with HL (2011-2023).
- Risk stratification into low (R1), intermediate (R2), and high (R3) groups.
- Comparison of ABVD and HL-2013 chemotherapy regimens.
- Prognostic factor analysis using Cox regression.
Main Results:
- Overall complete response (CR) rates were 42% (2 cycles) and 68% (4 cycles).
- HL-2013 regimen showed higher CR rates in the low-risk (R1) group compared to ABVD.
- 5-year event-free survival (EFS) was 83%, overall survival 97%, and freedom from treatment failure 88%.
- Large tumor mass and failure to achieve CR after 4 cycles were independent risk factors for lower EFS.
Conclusions:
- Pediatric Hodgkin lymphoma generally exhibits a favorable prognosis.
- Large tumor burden and incomplete treatment response are indicators of a poorer prognosis in pediatric HL.
Objectives:
To investigate the clinicopathological characteristics and prognostic factors of pediatric Hodgkin lymphoma (HL).
Methods:
A retrospective analysis was conducted on the clinical data of children with newly diagnosed HL from January 2011 to December 2023 at four hospitals: Fujian Medical University Union Hospital, Fujian Medical University Zhangzhou Hospital, First Affiliated Hospital of Xiamen University, and Fujian Children's Hospital. Patients were categorized into low-risk (R1), intermediate-risk (R2), and high-risk (R3) groups based on HL staging and pre-treatment risk factors. The patients received ABVD regimen or Chinese Pediatric HL-2013 regimen chemotherapy. Early treatment response and long-term efficacy were assessed, and prognostic factors were analyzed using the Cox proportional hazards regression model.
Results:
The overall complete response (CR) rates after 2 and 4 cycles of chemotherapy were 42% and 68%, respectively. Compared with the ABVD regimen group, patients treated with the HL-2013 regimen in the R1 group showed significantly higher CR rates after both 2 and 4 cycles (P<0.05). However, no statistically significant differences in CR rates were observed between the two regimens in the R2 and R3 groups (P>0.05). The 5-year event-free survival (EFS) rate, overall survival rate, and freedom from treatment failure rate were 83%±4%, 97%±2%, and 88%±4%, respectively. Cox analysis indicated that the presence of a large tumor mass at diagnosis and failure to achieve CR after 4 cycles of chemotherapy were independent risk factors for lower EFS rates (P<0.05).
Conclusions:
Pediatric HL generally has a favorable prognosis. The presence of a large tumor mass at diagnosis and failure to achieve CR after 4 cycles of chemotherapy indicate poor prognosis.
Related Concept Videos
01:21Cancer Survival Analysis
01:20Comparing the Survival Analysis of Two or More Groups
02:56Treatment Resistant Cancers